Eli Lilly News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Orderbuch

Analysen

Historisch

24.04.18	Lilly Reports Strong First-Quarter 2018 Results, Raises EPS Guidance (PR Newswire)
24.04.18	AAN 2018: Lilly's Galcanezumab Significantly Reduced Monthly Migraine Headache Days in Patients with Migraine Who Previously Failed to Respond to Multiple Preventive Therapies (PR Newswire)
24.04.18	PRTA Jolted, FDA Strikes Down PFE's Herceptin Biosimilar, No Relief Yet For KMDA (RTTNews)
24.04.18	FDA Panel Backs Lower Dose Of Lilly-Incyte Arthritis Drug, But Not Higher Dose (RTTNews)
24.04.18	FDA Advisory Committee Recommends the Approval of Baricitinib 2mg, but not 4mg, for the Treatment of Moderately-to-Severely Active Rheumatoid Arthritis (PR Newswire)
23.04.18	Elanco Announces Addition of Chief Financial Officer (PR Newswire)
21.04.18	An Ear To The Pharma: 10 Stocks To Watch (BHVN, LLY, TOCA, ALDR…) (RTTNews)
20.04.18	Lilly Reports Additional Top-Line Results from CYRAMZA® (ramucirumab) Phase 3 RANGE Study in Advanced or Metastatic Urothelial Cancer (PR Newswire)
20.04.18	Lilly to Present Phase 3 Data at AAN 2018 Reinforcing Commitment to New, Innovative Therapies in Migraine (PR Newswire)
19.04.18	Moody's: Stable outlook for global pharmaceuticals, M&A event risk is rising (Moodys)
16.04.18	Boehringer Ingelheim and Lilly announce an academic collaboration with University of Oxford to investigate the effects of Jardiance® in adults with chronic kidney disease (PR Newswire)
15.04.18	St. Baldrick's Foundation Commits $8 million to Support Pediatric Cancer Dream Team with Stand Up To Cancer (PR Newswire)
05.04.18	CNAT Disappoints, EBIO To Report VISTA Data In May, PRTK To Face FDA In Oct. (RTTNews)
04.04.18	Lilly Confirms Date and Conference Call for First-Quarter 2018 Financial Results Announcement (PR Newswire)
04.04.18	Eli Lilly, Sigilon Announce Global Collaboration - Quick Facts (RTTNews)
04.04.18	Lilly and Sigilon Therapeutics Announce Strategic Collaboration to Develop Encapsulated Cell Therapies for the Treatment of Type 1 Diabetes (PR Newswire)
04.04.18	Eli Lilly: CYRAMZA Phase 3 REACH-2 Study Meets Primary Endpoint - Quick Facts (RTTNews)
04.04.18	Lilly Announces CYRAMZA® (ramucirumab) Phase 3 REACH-2 Study in Second-Line Hepatocellular Carcinoma Patients Met Overall Survival Endpoint (PR Newswire)
03.04.18	Improving Cardiology Care: BIOTRONIK US to Distribute Aziyo ECM Envelopes (PR Newswire)
03.04.18	Will These Drugs Reach Blockbuster Status? (RTTNews)
28.03.18	Biotech Stocks Facing FDA Decision In April (RTTNews)
23.03.18	Un plan audacieux pour le Québec! - Plan d'action gouvernemental en entrepreneuriat (PR Newswire)
09.03.18	Maura Dickler, M.D., to become Vice President of Late Phase Development at Lilly Oncology (PR Newswire)
08.03.18	EFSD, JDRF, Lilly Extend Collaboration Supporting Type 1 Diabetes Research (RTTNews)
08.03.18	EFSD, JDRF and Lilly Extend Collaboration Supporting Type 1 Diabetes Research (PR Newswire)
06.03.18	Boehringer Ingelheim and Lilly expand heart failure program for Jardiance® with new exercise capacity trials (PR Newswire)
26.02.18	Eli Lilly Announces Additional FDA Approval For Verzenio - Quick Facts (RTTNews)
26.02.18	Lilly Receives Additional FDA Approval for VerzenioTM (abemaciclib), as Initial Treatment for Advanced Breast Cancer (PR Newswire)
26.02.18	Eli Lilly Reports New Data From Trulicity Phase 3b Study - Quick Facts (RTTNews)
26.02.18	New Data Show Lilly's Trulicity® (dulaglutide) in Combination with an SGLT-2 Inhibitor Improves Blood Sugar Control in People with Type 2 Diabetes (PR Newswire)
21.02.18	Lilly to Participate in Barclays Global Healthcare Conference (PR Newswire)
20.02.18	Lilly to Participate in Cowen Health Care Conference (PR Newswire)
20.02.18	Survey Reveals Many People with Migraine Live with Pain Nearly Half of Every Month (PR Newswire)
19.02.18	Eli Lilly: Taltz Improves Sexual Health Of Genital Psoriasis Patients (RTTNews)
19.02.18	AAD 2018: Treatment with Lilly's Taltz® (ixekizumab) Resulted in Improvement in Impact of Genital Psoriasis on Sexual Activity (PR Newswire)
14.02.18	Lilly to Showcase New Data for Taltz® (ixekizumab) and Other Products Across Immunology Pipeline at AAD Annual Meeting (PR Newswire)
13.02.18	Eli Lilly: Taltz Phase 3 Study Meets Endpoints To Treat Ankylosing Spondylitis (RTTNews)
13.02.18	Lilly Announces Positive Top-Line Phase 3 Results for Taltz® (ixekizumab) in Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis) (PR Newswire)
31.01.18	MÄRKTE USA/Fed bremst Erholung an der Wall Street (Dow Jones)
31.01.18	MÄRKTE USA/Erholungsdynamik an der Wall Street lässt nach (Dow Jones)
31.01.18	Eli Lilly schreibt wegen US-Steuerreform Verlust (AWP) Die US-Steuerreform hat dem US-Pharmakonzern Eli Lilly im vierten Quartal einen hohen Verlust eingebrockt.» mehr
31.01.18	Lilly Lifts 2018 Profit View; Backs Revenue Outlook (RTTNews)
31.01.18	Eli Lilly And Co. Profit Rises In Q4 (RTTNews)
31.01.18	Lilly Reports Strong Fourth-Quarter and Full-Year 2017 Revenue Growth, Increases 2018 EPS Guidance (PR Newswire)
26.01.18	Lilly To Present At Leerink Partners Global Healthcare Conference (PR Newswire)
26.01.18	Elanco Announces Global Agreement with Ab E Discovery for New Technology (PR Newswire)
22.01.18	Eli Lilly Animal Health Unit Announces FDA Approval Of Credelio - Quick Facts (RTTNews)
22.01.18	Elanco Animal Health Announces U.S. Food and Drug Administration (FDA) Approval of Credelio® (lotilaner) to Treat and Protect Against Ticks and Fleas (PR Newswire)
22.01.18	Some Branded Drugs Going Generic In 2018 (RTTNews)
18.01.18	Elanco Innovations Named Best Products for 2017 (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’276.50	0.75 %	K V
Alcon	76.58	0.34 %	K V
Kuehne+Nagel Int	203.10	0.25 %	K V
Holcim	89.06	0.23 %	K V
Logitech Intl	75.00	0.19 %	K V
UBS Group	27.84	-1.17 %	K V
Sika	223.20	-1.33 %	K V
Nestle	73.96	-1.68 %	K V
Swiss Re	129.55	-1.82 %	K V
Givaudan	3’982.00	-1.95 %	K V

mehr

15:58		Euro STOXX 50-Handel aktuell: Euro STOXX 50 am Nachmittag mit Gewinnen
15:58		SMI aktuell: SMI verbucht nachmittags Verluste
12:26		Börse Europa in Grün: Euro STOXX 50 steigt mittags
12:26		Börse Zürich: SMI präsentiert sich leichter
09:29		Optimismus in Frankfurt: DAX zum Handelsstart fester
09:29		Verluste in Zürich: SMI beginnt Mittwochshandel im Minus
09:29		Pluszeichen in Frankfurt: Anleger lassen LUS-DAX zum Start steigen
09:29		Verluste in Europa: Euro STOXX 50 beginnt die Mittwochssitzung im Minus

15:58

Euro STOXX 50-Handel aktuell: Euro STOXX 50 am Nachmittag mit Gewinnen

15:58

SMI aktuell: SMI verbucht nachmittags Verluste

12:26

Börse Europa in Grün: Euro STOXX 50 steigt mittags

12:26

Börse Zürich: SMI präsentiert sich leichter

09:29

Optimismus in Frankfurt: DAX zum Handelsstart fester

09:29

Verluste in Zürich: SMI beginnt Mittwochshandel im Minus